These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 2546278)

  • 1. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
    Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
    Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin.
    Hoet B; Falcon C; De Reys S; Arnout J; Deckmyn H; Vermylen J
    Blood; 1990 Feb; 75(3):646-53. PubMed ID: 2153424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Bourgain RH; Andries R; Decuyper K; De Clerck F
    J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
    Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
    J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
    Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor.
    Hoet B; Arnout J; Deckmyn H; Vermylen J
    Thromb Haemost; 1993 Nov; 70(5):822-5. PubMed ID: 8128441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. R68070, a combined thromboxane/endoperoxide receptor antagonist (TRA) and thromboxane synthase inhibitor (TSI), prolongs the bleeding time more than aspirin in man.
    Hoet B; Arnout J; Vermylen J
    Prog Clin Biol Res; 1989; 301():573-7. PubMed ID: 2552467
    [No Abstract]   [Full Text] [Related]  

  • 16. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
    Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
    Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
    Hornby EJ; Foster MR; McCabe PJ; Stratton LE
    Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM; Wu TS; Teng CM
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.